ClinicalTrials.gg
CompletedNCT01163032Updated Oct 16, 2014Results posted

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

A Phase 3 interventional study of tasimelteon and Placebo in Non-24-Hour Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed at 28 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Enrollment
16th of 54
136 · median 50
Started
2010
with 2 others
Phase 3
10 of 69
1 open now
Registered
20th of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 16th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 20th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder

Read the detailed description

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, randomized, double-masked, placebo-controlled, parallel study. The study has two phases: the pre-randomization phase followed by either the randomization phase or the open-label extension (OLE). The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated, a circadian period (τ) estimation segment, and a variable-length in-phase transition segment in which subjects will wait to start treatment until their circadian phase is aligned with their target bedtime. Subjects that meet all entry criteria for the study will enter the randomization phase. During the randomization phase, subjects will be asked to take either 20 mg tasimelteon or placebo approximately 1 hour prior to their target bedtime for 26 weeks in a double-masked fashion. Subjects who have a τ greater than 24.0 and meet all entry criteria but that are ineligible for the randomization phase due to their τ estimate may be given the opportunity to participate in the OLE phase. During the OLE phase, subjects will take open-label 20mg tasimelteon for 26 weeks.

03

Conditions studied

  • Non-24-Hour Sleep-Wake Disorder

Keywords

  • Blindness
  • Eye Diseases
  • Nap Disorders
  • Circadian Rhythm Disorders
  • Sleep disorders
  • Circadian Rhythm Sleep Disorders
  • Dyssomnias
  • Nervous System Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and acceptance to provide ;
  • No perception of light by the subject's own report;
  • Diagnosis of N24HSWD as determined by:

    1. History (within the last 3 months) of trouble sleeping at night difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire and
    2. Urinary aMT6s demonstrates a progressive delay of the aMT6 acrophase time.
  • Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;
  • Fluent in English;

Exclusion criteria

Exclusion Criteria:

  • Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;
  • Current cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
  • History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
  • History of intolerance and/or to melatonin or melatonin agonists;
  • Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;
  • Unable to perform calls to the study IVR system to report questionnaire results;
  • Exposure to any drug, including placebo, within 30 days or 5 half lives (whichever was longer) of screening;
  • Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle
  • Use of melatonin or melatonin agonist
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    tasimelteon

    20 mg tasimelteon capsules, PO daily for 6 months

    Drug: tasimelteon

  • Placebo comparator
    placebo

    Placebo capsules, PO daily for 6 months

    Drug: Placebo

Interventions

  • 20 mg tasimelteon capsules, PO daily for 6 months

    Also known as: VEC-162

  • DrugPlacebo

    Placebo capsules, PO daily for 6 months

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Entrained as Assessed by Urinary aMT6

    Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.

    Time frame: 1 month

  2. Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS

    Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of Patients Entrained as Assessed by Urinary Cortisol

    Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four 48 hour periods, approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.

    Time frame: 1 month

  2. Average Clinical Global Impression of Change (CGI-C)

    CGI-C scores range from 1 (very much improved) to 7 (very much worse). The average post-randomization score was obtained for each patient by averaging the last 2 scheduled assessments (Day D112 and Day D183). Lower number indicates improvement.

    Time frame: Day 112 and 183

  3. Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes)

    The sleep/wake response represents measurement of the combined improvement in the nighttime sleep duration and daytime sleep duration. Individuals that have an improvement in nighttime sleep and daytime sleep, defined as an increase of 90 minutes or more in the lower quartile of subjective nighttime total sleep time (LQ-nTST) and a decrease of 90 minutes or more in the upper quartile of daytime total sleep duration (UQ-dTSD) are considered to be a responder.

    Time frame: 6 months

  4. Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)

    LQ-nTST measures the difference in average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) between the randomized phase (6 months)and the screening phase (\~ 6 weeks). The higher number indicates improvement.

    Time frame: 6 months

  5. Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)

    UQ-dTSD measures the difference in average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) between the randomized phase (6 months) and the screening phase (\~ 6 weeks). Lower number indicates improvement.

    Time frame: 6 months

  6. Average Midpoint of Sleep (MoST)

    Midpoint of Sleep Timing (MoST) is the measurement of the average midpoint of sleep time relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.

    Time frame: 6 months

  7. Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)

    Adverse events were recorded in the source documents from the time of the patient's informed consent signature until the end of the patient's study participation. An AE was defined as any untoward medical occurrence in a clinical investigation patient who does not necessarily have causal relationship with treatment.

    Time frame: 6 months

Other outcomes

  1. Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS

    Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 2 on the Non-24 Clinical Response Scale (N24CRS) which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.

    Time frame: 6 months

  2. Proportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS)

    Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline

    Time frame: 6 months

  3. Proportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS)

    Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline

    Time frame: 6 months

07

Results

Posted Oct 16, 2014

Participant flow

\*Various category for the Randomization Phase: 4 patients in each treatment group discontinued due to study termination by the sponsor and 1 patient in the tasimelteon group discontinued due to travel across multiple time zones

Randomization Phase
Participant flow — Randomization Phase
MilestoneTasimelteon (Randomized)Placebo (Randomized)Open Label Tasimelteon
Started42420
Completed32300
Not completed10120
Withdrew: Withdrawal by subject230
Withdrew: Adverse event330
Withdrew: Protocol violation010
Withdrew: Various*540
Withdrew: Unsatisfactory therapeutic effect010
Open Label Extension Phase
Participant flow — Open Label Extension Phase
MilestoneTasimelteon (Randomized)Placebo (Randomized)Open Label Tasimelteon
Started0055
Completed0039
Not completed0016
Withdrew: Adverse event003
Withdrew: Withdrawal by subject003
Withdrew: Protocol violation001
Withdrew: Study termination007
Withdrew: Unsatisfactory therapeutic effect002

Outcome measures

PrimaryProportion of Patients Entrained as Assessed by Urinary aMT6

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.

Time frame:
1 month
Reported as:
Number · percentage of patients
Proportion of Patients Entrained as Assessed by Urinary aMT6
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients Entrained as Assessed by Urinary aMT6202.6
PrimaryProportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS

Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS23.70
Other pre-specifiedProportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS

Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score ≥ 2 on the Non-24 Clinical Response Scale (N24CRS) which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening τ from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 2 on N24CRS28.90
Other pre-specifiedProportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS)

Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS)
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients With a Clinical Response (Score of ≥ 3 on N24CRS)28.92.9
SecondaryProportion of Patients Entrained as Assessed by Urinary Cortisol

Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four 48 hour periods, approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline τ value less than 24.1 and a 95% CI that included 24.0.

Time frame:
1 month
Reported as:
Number · percentage of patients
Proportion of Patients Entrained as Assessed by Urinary Cortisol
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients Entrained as Assessed by Urinary Cortisol17.52.6
SecondaryAverage Clinical Global Impression of Change (CGI-C)

CGI-C scores range from 1 (very much improved) to 7 (very much worse). The average post-randomization score was obtained for each patient by averaging the last 2 scheduled assessments (Day D112 and Day D183). Lower number indicates improvement.

Time frame:
Day 112 and 183
Reported as:
Mean · score
Average Clinical Global Impression of Change (CGI-C)
scoreTasimelteon (Randomized)Placebo (Randomized)
Average Clinical Global Impression of Change (CGI-C)2.6 ± 0.203.4 ± 0.21
SecondaryProportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes)

The sleep/wake response represents measurement of the combined improvement in the nighttime sleep duration and daytime sleep duration. Individuals that have an improvement in nighttime sleep and daytime sleep, defined as an increase of 90 minutes or more in the lower quartile of subjective nighttime total sleep time (LQ-nTST) and a decrease of 90 minutes or more in the upper quartile of daytime total sleep duration (UQ-dTSD) are considered to be a responder.

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes)
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 90 Minutes) and UQ-dTSD (≤ 90 Minutes)13.22.9
SecondaryAverage Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)

LQ-nTST measures the difference in average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) between the randomized phase (6 months)and the screening phase (\~ 6 weeks). The higher number indicates improvement.

Time frame:
6 months
Reported as:
Mean · minutes
Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)
minutesTasimelteon (Randomized)Placebo (Randomized)
Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)56.80 ± 9.30517.08 ± 9.702
SecondaryAverage Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)

UQ-dTSD measures the difference in average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) between the randomized phase (6 months) and the screening phase (\~ 6 weeks). Lower number indicates improvement.

Time frame:
6 months
Reported as:
Mean · minutes
Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)
minutesTasimelteon (Randomized)Placebo (Randomized)
Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)-46.48 ± 6.595-17.87 ± 6.889
SecondaryAverage Midpoint of Sleep (MoST)

Midpoint of Sleep Timing (MoST) is the measurement of the average midpoint of sleep time relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.

Time frame:
6 months
Reported as:
Mean · minutes
Average Midpoint of Sleep (MoST)
minutesTasimelteon (Randomized)Placebo (Randomized)
Average Midpoint of Sleep (MoST)35.00 ± 5.31314.48 ± 5.547
Post-hocProportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 45 Minutes) and UQ-dTSD (≤ 45 Minutes)

Responder analysis with responder defined as an increase of 45 minutes or more in (LQ-nTST) and a decrease of 45 minutes or more in (UQ-dTSD).

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 45 Minutes) and UQ-dTSD (≤ 45 Minutes)
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (≥ 45 Minutes) and UQ-dTSD (≤ 45 Minutes)31.68.8
Other pre-specifiedProportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS)

Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below). LQ-nTST: \>45 minutes increase in average nighttime sleep duration; UQ-dTSD: \>45 minutes decrease in average daytime sleep duration; MoST: \>30 minutes increase and a standard deviation \<2 hours during double-masked phase (6 months); CGI-C: \<2.0 from the average of D112 and Day 183 compared to baseline

Time frame:
6 months
Reported as:
Number · percentage of patients
Proportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS)
percentage of patientsTasimelteon (Randomized)Placebo (Randomized)
Proportion of Patients With a Clinical Response (Score of ≥ 2 on N24CRS)57.920.6
SecondaryNumber of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)

Adverse events were recorded in the source documents from the time of the patient's informed consent signature until the end of the patient's study participation. An AE was defined as any untoward medical occurrence in a clinical investigation patient who does not necessarily have causal relationship with treatment.

Time frame:
6 months
Reported as:
Number · participants
Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)
participantsOpen Label Tasimelteon
Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)37

Adverse events

Collected over 1st dose to 30 days following last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tasimelteon (Randomized)—4/42 (9.5%)20/42 (47.6%)
Placebo (Randomized)—2/42 (4.8%)13/42 (31%)
Open Label Tasimelteon—2/54 (3.7%)21/54 (38.9%)
Most frequent serious events
Most frequent serious events
EventTasimelteon (Randomized)Placebo (Randomized)Open Label Tasimelteon
Procedural PainInjury, poisoning and procedural complications0/421/420/54
Small Intestinal ObstructionGastrointestinal disorders0/421/420/54
SyncopeNervous system disorders1/420/420/54
Acute Lymphocytic LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/420/420/54
CholecystitisHepatobiliary disorders1/420/420/54
DiverticulitisInfections and infestations1/420/420/54
Serotonin SyndromeNervous system disorders0/420/421/54
Transient Ischaemic AttackNervous system disorders0/420/421/54
Most frequent other events
Most frequent other events
EventTasimelteon (Randomized)Placebo (Randomized)Open Label Tasimelteon
HeadacheNervous system disorders7/423/424/54
NasopharyngitisInfections and infestations3/424/425/54
Alanine aminotransferase increasedInvestigations4/422/422/54
Urinary tract infectionInfections and infestations3/421/425/54
NauseaGastrointestinal disorders1/423/420/54
Asparate aminotransferase increasedInvestigations3/422/423/54
Oedema peripheralGeneral disorders3/422/420/54
Upper respiratory tract infectionInfections and infestations3/420/422/54
Gamma-glutamyltransferase increasedInvestigations0/422/423/54
Abnormal dreamsPsychiatric disorders2/420/423/54

Baseline characteristics

52 patients entered the OLE Phase from screening and 3 patients rolled over after completing the Randomization Phase (2:tasimelteon; 1:placebo). For this analysis, 3 patients are included in the randomized arms and not the OLE. A separate analysis has been done for both age and gender for the 3 subjects (Rand to OLE).

Age, Continuous
Age, Continuous(years)Tasimelteon (Randomized)Placebo (Randomized)Open Label TasimelteonTotal
Mean50.8 ± 12.6350.7 ± 13.1550.37 ± 13.1750.6 ± 12.91
Age, Customized
Age, Customized(years)Tasimelteon (Randomized)Placebo (Randomized)Open Label TasimelteonTotal
Rand to OLE42.00 ± 5.6654.00 ± NANA ± NA46.00 ± 8.00
Sex/Gender, Customized
Sex/Gender, Customized(participants)Tasimelteon (Randomized)Placebo (Randomized)Open Label TasimelteonTotal
Rand to OLE (Female)0000
Rand to OLE (Male)2103
Sex: Female, Male
Sex: Female, Male(Participants)Tasimelteon (Randomized)Placebo (Randomized)Open Label TasimelteonTotal
Female18172560
Male24252776
08

Study locations

28 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • SDS Clinical Trials Inc.
    Orange, California 92868, United States
  • VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)
    Palo Alto, California 94304, United States
  • St. Johns Sleep Disorder Center - St. Johns Medical Plaza
    Santa Monica, California 90404, United States
  • Radiant Research - Denver
    Denver, Colorado 80239, United States
  • PAB Clinical Research Inc.
    Brandon, Florida 33511, United States
  • Kendall South Medical Center, Inc.
    Miami, Florida 33175, United States
  • Ocean Sleep Disorders Center - Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Sleep Disorders Center Of Georgia
    Atlanta, Georgia 30342, United States
  • Suburban Lung Associates SC (Chicago Metropolitan Area)
    Elk Grove Village, Illinois 60007, United States
  • The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)
    Chevy Chase, Maryland 20815, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Michigan Head-Pain Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)
    Chesterfield, Missouri 63017, United States
  • New York Eye and Ear Infirmary
    New York, New York 10003, United States
  • Tri-State Sleep Disorders Center
    Cincinnati, Ohio 45246, United States
  • Ohio Sleep Medicine Institute (Columbus Metropolitan Area)
    Dublin, Ohio 43017, United States
  • Lynn Health Science Institute
    Oklahoma city, Oklahoma 73112, United States
  • Columbia Research Group Inc.
    Portland, Oregon 97239, United States
  • Center For Sleep Medicine at Chestnut Hill Hospital
    Philadelphia, Pennsylvania 19118, United States
  • Consolidated Clinical trials
    Pittsburgh, Pennsylvania 15221, United States
  • SleepMed, Inc. - Columbia
    Columbia, South Carolina 29201, United States
  • Todd J. Swick, M.D., P.A.
    Houston, Texas 77063, United States
  • Advanced Sleep Research GmbH
    Berlin, 10117, Germany
  • Bergmannsheil University Hospital - Medical Clinic III
    Bochum, 44789, Germany
  • Klinische-Forschung Hannover Mitte
    Hannover, 30159, Germany
  • Universitaetsklinikum Glesen and Marburg gmbH/Schlaflabor - Sleep Lab University Marburg
    Marburg, 35043, Germany
  • Bonomed Studiezentrum
    Munich, 80331, Germany
09

References and documents

Publications

  • Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4. PubMed 26466871 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 11 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2010
First posted
Jul 15, 2010
Start
Aug 2010
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results delay requested
May 21, 2013
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01163032
Responsible party
Sponsor
First posted
Jul 15, 2010
Start date
Aug 2010
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Oct 16, 2014
Last update
Oct 16, 2014

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion